PTC124 (Ataluren) is a novel small molecular CFTR-G542X nonsense allele inhibitor. In safety pharmacology studies in rats and dogs, oral administration of PTC124 (Ataluren) induces no adverse neurological, pulmonary, or cardiovascular effects at doses through 1500 mg/kg. In toxicology studies in rats and dogs at oral doses through 1500 mg/kg for 28 days, PTC124 (Ataluren) has shown good tolerability. Both PTC124 doses were similarly active, improving total chloride transport with a combined mean change of -5.4 mV (p<0.001), and on-treatment responses (at least -5 mV improvement) and hyperpolarisations (values more electrically negative than -5 mV) in 61% (p<0.001) and 56% (p = 0.002) of patients. CFTR function was greater with time and was accompanied by trends toward improvements in pulmonary function and CF-related coughing. The high readthrough efficiency of PTC124 in combination with excellent biocompatibility makes it a promising therapeutic agent for PTCs in USH1C.
Cell Experiment | |
---|---|
Cell lines | Grip-Tite 293 cells transfected with the pFLuc190UGA construct |
Preparation method | Luciferase Reporter Assays. All cell-based assays were performed in 1,536-well plates with an assay volume of 4.5 μL per well. Comparative cell-based experiments were performed with cells from the same batch of transfected cells to control for transfection efficiency. Cells were incubated with compound or antibiotic for 16–72 h. In experiments with Grip-Tite cells, cells were washed with PBS before the addition of detection reagent containing the FLuc or RLuc substrate. Luminescence from luciferase activity was detected by using ViewLux (PerkinElmer). Experimental plates contained the transcriptional activator MS-275 as a positive control and DMSO-treated cells or mock-transfected cells as a negative control. Percentage activity was defined as the percentage signal above DMSO-treated cells. |
Concentrations | 0~100μM |
Incubation time | 24 hr |
Animal Experiment | |
---|---|
Animal models | Cftr−/− hCFTR-G542X mice |
Formulation | saline |
Dosages | 15, 30 or 60mg/kg initiated 16 days after birth and continued once daily until the animals were killed |
Administration | Subcutaneous injections |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Molecular Weight | 284.24 |
Formula | C15H9FN2O3 |
CAS Number | 775304-57-9 |
Purity | >99% |
Solubility | DMSO ≥47 mg/mL |
Storage | at -20°C |
Related CFTR Products |
---|
CP-628006
The CFTR potentiator CP-628006 enhances CFTR function in cystic fibrosis patient-derived air chamber cells by a mechanism of action different from that of existing potentiators such as ivacaftor. |
Icenticaftor
Icenticaftor (QBW251) is an oral enhancer of the cystic fibrosis transmembrane conductance regulator (CFTR) channel with an EC50 of 79 nM for F508del and 497 nM for G551D CFTR. Icenticaftor can be used in chronic obstructive pulmonary disease (COPD) and cystic fibrosis studies. |
NJH-2-057
NJH-2-057 is a conjugate of the deubiquitinase OTUB1 covalent ligand-linked lumacaftor, which stabilizes mutant CFTR proteins in cells. |
GLPG2451
GLPG2451 is an enhancer of cystic fibrosis transmembrane conductance regulator (CFTR) and effectively enhances cryo-rescued F508del CFTR with an EC50 of 11.1 nM. |
FDL169
FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.